Answers are grounded in this paper and cite their sources.
Investigates diarylheptanoid effects on colitis and cancer prevention, suggesting new treatments.
Diarylheptanoids are bioactive compounds primarily found in the rhizomes of Curcuma species and are traditionally used to treat inflammatory conditions. This study investigated the chemopreventive effects of 1,7-diphenyl-(4E, 6E)-4,6-heptadien-3-one (DPH), a diarylheptanoid isolated from Curcuma comosa ethanol extract (CCE), using in vitro and in vivo models. CCE/DPH administration significantly alleviated colitis and delayed colitis-associated colorectal tumorigenesis, accompanied by reduced expression of proinflammatory cytokines and mediators. Network pharmacology and experimental validation suggested potential involvement of the Toll-like receptor 4/mitogen-activated protein kinase/nuclear factor kappa B/signal transducer and activator of transcription 3 axis as a potential therapeutic target. Additionally, CCE/DPH upregulated the expression of the phase II antioxidant enzymes and tight junction proteins. Microbiome analysis revealed that CCE/DPH was associated with partial improvements in the gut microbial composition and metabolite profiles in experimental models. Overall, these findings support the preventive potential of CCE and DPH against experimental colitis and colitis-associated colorectal cancer.
No takes yet. Share an insight, caveat, or question.
Truong et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: